Head-To-Head Survey: Halozyme Therapeutics (NASDAQ:HALO) versus Soligenix (NASDAQ:SNGX)

Halozyme Therapeutics (NASDAQ:HALO) and Soligenix (NASDAQ:SNGX) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

Earnings and Valuation

This table compares Halozyme Therapeutics and Soligenix”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.40 billion	8.23	$316.89 million	$3.93	25.67
Soligenix	$120,000.00	39.64	-$11.08 million	($0.98)	-0.33

Halozyme Therapeutics has higher revenue and earnings than Soligenix. Soligenix is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Halozyme Therapeutics and Soligenix, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	2	3	7	1	2.54
Soligenix	1	0	0	0	1.00

Halozyme Therapeutics presently has a consensus target price of $108.18, indicating a potential upside of 7.26%. Given Halozyme Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Halozyme Therapeutics is more favorable than Soligenix.

Profitability

This table compares Halozyme Therapeutics and Soligenix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	26.93%	751.81%	23.84%
Soligenix	N/A	-165.32%	-97.40%

Risk and Volatility

Halozyme Therapeutics has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Comparatively, Soligenix has a beta of 2.04, suggesting that its share price is 104% more volatile than the S&P 500.

Institutional and Insider Ownership

97.8% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 3.6% of Soligenix shares are owned by institutional investors. 2.5% of Halozyme Therapeutics shares are owned by company insiders. Comparatively, 1.9% of Soligenix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Halozyme Therapeutics beats Soligenix on 13 of the 15 factors compared between the two stocks.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing drug-delivery technologies and medicines. Its ENHANZE platform uses a recombinant human hyaluronidase enzyme, rHuPH20, to temporarily modify tissue under the skin and help enable the subcutaneous administration of certain biologic medicines that might otherwise require intravenous infusion. Halozyme licenses ENHANZE to pharmaceutical and biotechnology partners, which use the technology in their own products. The company also markets Hylenex recombinant, a hyaluronidase product used to facilitate the dispersion and absorption of other injected medicines and fluids.

About Soligenix

Soligenix, Inc. is a U.S.-based biopharmaceutical company focused on developing treatments for rare diseases and serious medical conditions with limited therapeutic options. The company’s programs are primarily aimed at immunology, inflammation, infectious diseases and oncology, with an emphasis on advancing candidates through clinical development and regulatory approval. Soligenix’s pipeline has included SGX301, a synthetic hypericin-based photodynamic therapy being developed for cutaneous T-cell lymphoma; SGX942, an innate defense regulator investigated for inflammatory conditions such as oral mucositis; and SGX945, a related candidate studied for Behçet’s disease.